-
 Ignt!!! New news
YUCAIPA, Calif., Oct. 14, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading Global Medical Device manufacturer focused in the $4 billion Respiratory Market for the growing ageing and emerging markets for Home (DME), Hospital and Aviation Industries, announced today that the company has received a proposal from a leading manufacturer to help reduce production costs and material costs by 50% for the manufacture of the Oxyview and the Oxyview Nasal Cannula.
Related Quotes
Symbol Price Change
IGNT.PK 0.0034 0.0000
{"s" : "ignt.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""}
As a part of improving product quality in large production, and reducing material and production costs to be more competitive in the respiratory marketplace, the company has received a proposal from a leading respiratory equipment manufacturer based in Pomona-California. The company CEO, and some of the management staff received a proposal on Wednesday last week to manufacture both the Oxyview and the Oxyview Nasal Cannula at 50% of the original costs from its current manufacturer and supplier. On Friday last week, they had a meeting in Pomona with the new manufacturer to discuss the new manufacturing and distribution of Oxyview and the new Oxyview Nasal Cannula.
"Now that we are selling our respiratory products, and sales have escalated, we must reduce our cost of goods sold in order to increase our profit margins and decrease the costs to our dealers and buyers. This change will give the company a stronger foot-hold in the market. We have a proprietary product and there is nothing in the marketplace that can compete with our device. We have gained support for all sectors of our industry, inclusive of leading respiratory equipment manufacturers, clinical foundations and more important, our shareholders," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.
-
Ignt news
New news after close yesterday. Looks to be another good day for IGNT.
-
IGNT - Chart
-
IGNT - Company Overview
Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the US, and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing US and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adult, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million US patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
-
ignt
iv been on and off with them for a while now and they have been good to me but With them receving that proposal to reduce prodution and material cost by 50% along with sales going up to give them a foothold in the market im back on again
-
ignt
iv been on and off with them for a while now and they have been good to me but With them receving that proposal to reduce prodution and material cost by 50% along with sales going up to give them a foothold in the market im back on again
-
IGNT-Ingen Technologies,Inc
IGNT should have a great run tomorrow- Stock I hear is coming with some possible super news at the close tomorrow and stock is positioning itself for a great run next week-hoping for more news next week as well as some price appreceation- watch for it!!
-
IGNT - Company Overview
Ingen Technologies brings over 20 years of experience and dedication to the design and support of medical devices, Ingen has helped many medical professionals meet clinical and economic objectives.
Ingen has developed medical products that provide a valuable benefit to the patient and cost savings to the insurance companies, Medicare and essentially the tax payer. The medical products provide a focus for the ever-increasing elderly population. These products are superior to any of our competition and they allow for effective medical product availability to seniors.
Ingen’s Mission: Our Commitment to Customers
Ingen is committed to meeting the needs of our customers through ongoing product innovation and support. Ingen distributes its products through a national distributor network domestically and in Canada, Asia and European Communities. Ingen’s commitment to customers continues beyond the sale of our product.
The Beginning
Ingen, originally a privately owned company founded for the purpose of providing medical solutions for our growing healthcare market, is now a publicly traded company and growing medical device manufacturer. In 1999, Ingen founders invested several millions of dollars in the research and development of state-of-the-art respiratory monitoring devices, with a focus on helping patients and preventing unnecessary costs to the healthcare system. With multiple patents, FDA classification and certifications, Ingen is the largest manufacturer of gravity-independent in-line oxygen flow meters, meeting the demand of the growing patient population and service providers. Our products are manufactured in the USA.
Our Capabilities
We are proud of our capabilities in gas flow-meter technology and wireless digital data transfer of gas flow rate processing. Ingen is the first company to patent and develop transducers that detect oxygen flow rate and provide data transfer. This has revolutionized the oxygen therapy market providing user friendly solutions in monitoring oxygen levels and oxygen delivery systems.
Ingen Technologies, Inc. introduces Oxyview® , the World's First Patient In-Line Oxygen Flow-Meter. Another innovative respiratory product manufactured in the USA by Ingen Technologies; providing more confidence and assurance to patients using oxygen. Oxyview® is reusable, requires no batteries, works all the time in any position with all liquid or gas O2 systems, and easily installs anywhere below the cannula nearest the patient where oxygen flow matters the most. Oxygen suppliers and patients will appreciate that Oxyview® prevents many unnecessary service calls.
Ingen Technologies is now offering a quality organic health supplement for patients using home oxygen therapy, and also to anyone else who is interested in healthy life styles. As a part of wellness, we are now offering the new Poga Moonga products. Poga Moonga includes a substance referred to as Moringa, and is extracted from the Moringa Tree. Ingen provides a drink or capsule that is efficiently absorbed by the bodies metabolism.
One bottle is 25.35 Ounces. The instructions say to take 1-3 oz daily, therefore one bottle should last between 8-25 days. A purchase includes 4 bottles or 1-3 months supply depending upon use.
Author Sanford Holst in “Moringa, Nature’s Medicine Cabinet,” writes,
"...it is said the Moringa tree prevent 300 diseases. Ancient Roman, Greek and Egyptian civilizations used...the (Moringa Tree)...It is best known as an excellent source of nutrition and a natural energy booster. Loaded with nutrients, vitamins and amino acids, it replenishes your body and provides what you need to through a hectic weekday or active weekend..." It produces long-lasting energy without hyperactivity...a nerve system at rest...a blood system not under pressure...a gland and hormone system in balance."
An L.A. Times article said,
Scientifically speaking, Moringa sounds like magic. It can rebuild weak bones, enrich anemic blood and enable a malnourished mother to nurse her staving baby. Doctors use it to treat diabetes in West Africa and high blood pressure in India...And, it’s not only good for you, it’s delicious." Mark Fritz, L.A. Times.
Perhaps the most remarkable thing about the Moringa is that it has such incredible health benefits over a wide-range of health issues. Here are but a few:
* NUTRITION AND ENERGY BOOST
While most people notice an energy boost right away, the nutritional results with undernourished people is staggering.
* DETOXIFICATION
In vitro studies show the Moringa’s ability to remove putrid waste from water. This is important for the planet. Over 6 million children are believed to die each year from infections caused by unclean water. It helps our bodies detoxify in much the same way.
* ANTIBIOTIC
Moringa works as a gentle, natural antibiotic,
See Eilert, U.,B. Wolters and A. Nahrstedt. “The antibiotic principle of seeds of Moringa oleifera and Moringa stenopetala.” Journal of Medicinal Plant Research, 42, pp 55-61. 1981
* SKIN TREATMENT
And, like Aloe Vera, Moringa is believed to have great healing benefits for the skin. Most of the research is on topical applications, but the healing properties would extend to the body itself.
* ANTI-INFLAMMATORY
Indian traditional medicines have long used the Moringa in treating the body’s inflammation. See, Udupa, S.L., A.L. Udupa and D.R. Kulkarni, “Studies on the anti-inflammatory and wound healing properties of Moringa oleifera and Aegle marmelos. Fitoterapia 65(2) pp 119-123.
* ULCERS
The anti-ulcer effect of Moringa was reported in 1995 in Phytotherapy research. An extract was taken from dried leaves and showed an impressive ability to heal ulcers in lab animals. Holst, p17.
* DIABETES
An extract from the Moringa leaf has been shown to be effective in lowering blood sugar levels with a space of 3 hours. Holst, pp17-18.
* SLEEP
The leaf of the Moringa has been shown to aid in a calmer nervous system providing an improving in sleep. Holst, p18
In short some studies have proved Moringa leaves effective for treating,
* Blood pressure
* Diabetes
* Colitis and Diarrhea
* Used as a diuretic
* Headache
* Glandular swelling
* Skin antiseptic
* Fevers
Seeds are used for,
* Fevers
* Tumors
* Rheumatism
* Skin diseases
* Prostate and bladder issues
Leadership
Scott R. Sand
Chief Executive Officer and Chairman of the Board
Thomas J. Neavitt
Chief Financial Officer
J.R. Marple
Senior Accountant
Ron Mitchell
Certified Public Accountant
William Denney
Auditor- Child, Van Wagoner and Bradshaw LLC
Christopher A. Wirth
Chief Operations Officer & Director
Bradley C. Klearman
Director and EVP of Sales & Distribution
David Wald
Office Manager
John Finazzo, MD
Director and Chairman of the Medical Advisory Board
Stephen O’Hara, MD
Director and Member of the Medical Advisory Board
Peter Wilke
Attorney
Donn Harms
Patent Attorney
Robert H. Sand
Chief Manufacturing Engineer
Richard Campbell
Product Design & Engineering
-
IGNT-Ingen Tech., Inc. news 10/20 pre-market
Ingen CEO Discusses Company Future on Live Radio
Listen to The Money Channel CEO Interview
Press Release
Source: Ingen Technologies, Inc.
On 8:00 am EDT, Tuesday October 20, 2009
YUCAIPA, Calif., Oct. 20, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries announced today that Scott Sand, CEO of Ingen Technologies, will talk about Ingen's future on the live radio broadcast of The Money Channel's American Scene Radio scheduled for this morning at 9:42 a.m. For more information, go to The Money Channel // American Scene Radio // WallStreetCast
"Ingen is growth oriented, and we have a spectacular 2010 ahead of us. With the introduction of our new Oxyview Nasal cannula, Ingen is establishing footsteps in the world of medical technology. We will have a series of live radio broadcasts scheduled from now through the middle of next year," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.
The Money Channel // American Scene Radio // WallStreetCast
Ingen Technologies,Inc. - Home
I am not a registered broker and my signatures are of my own opinion. Make your buys and sells as you see fit, never invest more than you can afford to loose.
-
IGNT-Ceo on Money Channel today
Today's Ingen CEO Live Interview With The Money Channel
CEO Talks About Increased Sales and Corporate Dedication to Growth
Press Release
Source: Ingen Technologies, Inc.
On 8:15 am EDT, Thursday October 22, 2009
YUCAIPA, Calif., Oct. 22, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries announced today that the CEO, Scott Sand, will present the Sales and Marketing program for the new Oxyview Nasal Cannula on the live broadcast of The Money Channel's American Scene Radio scheduled later today at 11:34 AM eastern standard time.
On October 31, 2009, Medco Forum will introduce the Oxyview Nasal Cannula at the 2009 Annual Meeting of the American College of Chest Physicians in San Diego-California. The American College of Chest Physicians (ACCP) is a multidisciplinary international medical society with more than 16,000 active members representing more than 100 countries.
On November 18, 2009, Emergo Group will introduce the new Oxyview Nasal Cannula at MEDICA in Germany. MEDICA is the center of attraction for all those involved in the health care industry. More than 135,000 visitors from over 100 countries are expected to again obtain information on all the current and future trends in in-patient and out-patient care at this annual event. With its extensive ancillary program, numerous special events, two major congresses and the largest product display in the industry, MEDICA is the hub of the medical trade.
On January 25, 2010, the Emergo Group will introduce the new Oxyview Nasal Cannula at Arab Health in Dubai. The Arab Health Exhibition & Congress is the largest healthcare exhibition in the Middle East, and the second largest in the world. Arab Health is viewed as a must-attend global event in the healthcare calendar. Established 35 years ago, it provides a platform for the world's leading manufacturers, wholesalers and distributors to meet the medical and scientific community in the Middle East and beyond.
The company advertising in COPD Digest was released on September 14, 2009 to approximately 185,000 clinicians, patients and medical managers and will continue throughout 2010 with a full page editorial and a second full page color ad for every issue. COPD Digest is published with the support of, and contributions from, organizations representing the entire COPD community with a national subscriber base of more than 180,000.
The advertising for Today's Senior Magazine was released September 28, 2009 to approximately 180,000 subscribers. The next issue will feature an introductory price of the Oxyview Nasal Cannula. Today's Senior Magazine is a senior magazine that provides important information, plus local and national products and services for people fifty and over, with 150,000 California subscribers and 30,000 Texas subscribers.
The company has front cover full page editorials with Medco Forum for the fall. Medco Forum is a well-respected medical newsletter written and edited by a select editorial team composed of both physicians and professional medical journalists. Its purpose is to provide healthcare professionals with an exclusive preview of the latest innovations in their medical field prior to their annual conference.
The company reported gross sales of $106,483 in the quarter ended August 31, 2009. This represented an increase from sales of $987 in the quarter ended August 31, 2008. Sales were further sparked by the introduction of an "all-in-one" Oxyview Nasal Cannula unit that includes a cannula with the Oxyview unit. Additional capital also enabled Ingen to increase the advertising and marketing of the Oxyview products. The company anticipates sales of Oxyview to increase from the current quarter's sales as they expand sales channels.
The total cost of sales was $38,804 in the quarter ended August 31, 2009 and the gross profit was $67,679 (a gross margin of 63.6%).
The selling, general and administrative expenses were $598,442 in the quarter ended August 31, 2009. This was an increase of approximately 53.79% from the selling, general and administrative expenses of $276,933 reported in the quarter ended August 31, 2008. The increase in SG&A was due, in part, to additional advertising and marketing fees and increased amounts paid for outside services.
The largest components of the SG&A are advertising, legal and professional services, travel associated with both sales and business development, outside services and salaries. Advertising expense increased from zero in the quarter ended August 31, 2008 to $67,679 in the quarter ended August 31, 2009. The company expects to continue advertising at current levels as the company promotes the new Oxyview Nasal Cannula.
The amounts paid for outside services increased to $163,922 in the quarter ended August 31, 2009 from $61,276 in the quarter ended August 31, 2008 (an increase of 168%). The company is utilizing more outside services for office growth and in the development of a sales and support staff for anticipated increases in sales.
The Company has recorded patents at a cost of $67,345. There are 3 issued patents (2 in the U.S. and 1 in China), and there are 7 pending patents combined in the U.S., Canada, Japan and Europe expected to be granted and issued in 2010. The patents have added value to the intellectual property and will strengthen the market share for the new Oxyview Nasal Cannula.
Medco Forum - About Us
American College of Chest Physicians
Welcome to the COPD Digest!
Senior Living : Retirement : Elderly Health : Today's Senior Magazine
MEDICA 2009 - Messe Düsseldorf North America
index
Ingen Technologies,Inc. - Home
About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adult, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
I am not a registered broker and my signatures are of my own opinion. Make your buys and sells as you see fit, never invest more than you can afford to loose.
|
Checking For Related Data... |
View Profile
View Forum Posts
Private Message
Reply With Quote
Posting Permissions
Bookmarks